
Opinion|Videos|April 14, 2025
Presented at ELCC 2025: Key Takeaways From KRYSTAL-7
Panelists discuss how response rates, progression-free survival, and overall survival data presented at the European Lung Cancer Conference (ELCC 2025) demonstrate meaningful clinical outcomes while highlighting important safety considerations for patients.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































